Entry-level genetic report providers from Prof. Roberto Grobman 2023: Our Story: FullDNA has identified the need for creating a tool for healthcare professionals to access useful valuable genetic data from the big data pool of 21 million publications and growing daily roughly 2.5 million new publications every year. Our Technology experts built a unique AI system that knows to compare results of genetic tests, such as sequencing and genotyping and translate them to useful & focused data for doctors into a variety of 25 different panels The gained knowledge of population characteristics, such as diseases probabilities, physical features, nutrition predisposition, Interacted with AI technology can extract comprehensive details on trends, such as longevity status of populations, medications that better work to individuals or groups, nutrition consuming habits, best sports for each individual, psychological features, etc. This technology can help countries plan the future of their investments in preventive medication for their population. Discover more details on Roberto Grobman CTO.
How will hospitals and doctors be able to use our DNA data? Imagine if our doctor and the hospitals treating us had additional insights into our individual response to medication. The opportunity to enhance our treatment plan could be really beneficial. In practice, right now, that could happen with a doctor or patient sharing their pharmacogenomics report. In order to be effective at scale we would need to see pharmacogenomics results and reports stored in a patient’s electronic health record.
High quality genomic variants report providers with Prof. Roberto Grobman: Risks and limitations: Tests may not be available for the health conditions or traits that interest you. This type of testing cannot tell definitively whether you will or will not get a particular disease. Results often need to be confirmed with genetic tests administered by a healthcare professional. The tests look only at a subset of variants within genes, so disease-causing variants can be missed. Unexpected information that you receive about your health, family relationships, or ancestry may be stressful or upsetting.
Consider the example of familial hypercholesterolemia (FH), a condition in which multiple variants of several different genes lead to markedly high cholesterol. This greatly increases the risk of heart attack, stroke, and other health problems. FH affects about one in 300 adults, which means it isn’t rare. Among adults who have the most common genetic variants that cause it, heart attack or sudden cardiac death may occur in middle age. Children who have a double dose of a gene variant linked to this condition may die of cardiovascular disease before age 20. Earlier treatments intended to reduce the risk of complications, such as cholesterol-lowering drugs, are available if a child or adult is known to have a mutation linked to FH.
Since the sequencing of the first genome, innovations have fuelled reduced sequencing times, which have in turn reduced costs. Today we are able to use that cutting-edge technology to understand how to use your DNA to live with the best possible health — to get the most out of your DNA and yourself. The road to DNA health testing: With anything that relates to clinical care, we always need sufficient evidence before we can ‘know’ something and make recommendations. In some cases, the research can take 10 years before there are proven outcomes, before it’s appropriate to bring to the general population or implement a large-scale deployment.
Our entry-level genetic report encompasses a basic set of relevant genomic variants for a variety of Lifestyle & Personal Traits Panels. First Reports provide patient-specific information, determined by his genetics, which allows the user to know what their genetic tendencies are, thus can aid in maintaining their Vitality and Beauty. The startup FullDNA, which works with genetic recognition, will work with the University of Washington to help combat covid-19. The institution received first place in the Super Business Round in Vale do Pinhão. After the award, the company signed a collaboration agreement with a university in the United States to discover which elements are capable of interfering with the coupling of the coronavirus to the human cell receptor. Find even more information at https://www.f6s.com/company/fulldna.